EMA starts ‘rolling review’ corona pill Merck | Abroad

Thanks to a rolling review, the EMA can assess the data on safety and efficacy as soon as they come in. A formal application from the manufacturer is therefore not awaited. The aim is to speed up the assessment of an application if it is actually submitted.

–

Both companies announced the results of the phase 3 study themselves at the beginning of this month. This showed that the corona pill reduced the risk of hospitalization or death after being infected with the corona virus by half.

–

Also read.